Jubilant Life Sciences Limited (JLL), an integrated pharmaceuticals and life sciences company, has appointed Gurpartap Singh Sachdeva (GP Singh) as chief executive officer of Jubilant Pharma Ltd, a 100 per cent wholly-owned subsidiary of JLL. Singh will have overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma Board. He will be based in the United States.
Prior to Jubilant, Singh had served as president of Sun Pharmaceuticals, USA and contributed to the growth of Sun’s US business. He has worked extensively both in India and in the US in various leadership roles pertaining to strategy, M&A, commercial and operations.
The appointment of Singhas CEO of Jubilant Pharma strengthens the management structure of the company and follows the appointment of Pramod Yadav and Rajesh Srivastava as co-CEOs of the life science ingredients business of JLL.
This is pursuant to the previously announced management consolidation of pharmaceuticals and life science ingredients under two independent verticals to decouple the pharmaceuticals segment from the life science ingredients segment thereby harnessing the true potential in each businesses to aid focused faster growth for the company.
Commenting on the occasion, Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences Limited said: “We are pleased to welcome Singh into the Jubilant family to complete our pharma consolidation. Our pharmaceuticals segment has attained significant scale and the businesses therein have great potential for growth. Singh’s rich experience in pharmaceuticals industry will help the company to enhance its focus and competitiveness thereby unlocking shareholder value.”